Edition:
United States

Amyris Inc (AMRS.OQ)

AMRS.OQ on NASDAQ Stock Exchange Global Select Market

0.35USD
25 Jul 2016
Change (% chg)

$-0.03 (-8.82%)
Prev Close
$0.39
Open
$0.38
Day's High
$0.38
Day's Low
$0.35
Volume
135,516
Avg. Vol
267,403
52-wk High
$2.57
52-wk Low
$0.31

AMRS.OQ

Chart for AMRS.OQ

About

Amyris, Inc. is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including... (more)

Overall

Beta: 0.97
Market Cap(Mil.): $81.87
Shares Outstanding(Mil.): 211.17
Dividend: --
Yield (%): --

Financials

  AMRS.OQ Industry Sector
P/E (TTM): -- 15.88 43.96
EPS (TTM): -1.41 -- --
ROI: -238.23 7.68 8.02
ROE: -- 9.45 8.91

BRIEF-American Refining Group invests in Novvi to accelerate Amyris commercialization of renewable base oil and lubricant platform

* American Refining Group invests in Novvi to accelerate Amyris commercialization of renewable base oil and lubricant platform

Jul 19 2016

BRIEF-Amyris entered into note purchase agreement with Foris Ventures LLC

* On June 24, 2016 entered into note purchase agreement with Foris Ventures LLC for sale of $5 million in aggregate principal amount of secured promissory notes

Jun 29 2016

BRIEF-Amyris Inc enters into strategic partnership agreement with Ginkgo Bioworks

* Amyris inc says on june 28, 2016 co entered into a strategic partnership agreement with ginkgo bioworks, inc

Jun 29 2016

BRIEF-Ginkgo Bioworks says partners with Amyris Inc

* Co, Amyris announced partnership, which will enable companies to jointly develop products

Jun 29 2016

BRIEF-Amyris announces long term collaboration with Givaudan

* Amyris announces long term, multi-million-dollar collaboration in cosmetic active ingredients with Givaudan Source text for Eikon: (Bengaluru Newsroom; +1 646 223 8780)

Jun 28 2016

BRIEF-Amyris announces collaboration with Johnson & Johnson Innovation

* Amyris announces collaboration with Johnson & Johnson innovation for biosynthetic drug discovery

Jun 06 2016

BRIEF-Amyris & CJ Cheiljedang creates manufacturing and sales partnership

* Amyris & cj cheiljedang corporation creating manufacturing and sales partnership

May 20 2016

BRIEF-Amyris signs five year Biofene supply agreement

* Amyris signs five year Biofene supply agreement with leading global nutraceuticals company with over $100 million of expected value Source text for Eikon: Further company coverage:

Apr 27 2016

BRIEF-Amyris announces $5 mln equity investment from Bill & Melinda Gates Foundation

* Amyris creates program to reduce the cost and increase access to leading malaria treatment

Apr 11 2016

BRIEF-Amyris files for non-timely 10-k - sec filing

* Expects to file annual report on form 10-k for fiscal year 2015 on or before fifteenth calendar day following form 10-k's due date Source text : http://1.usa.gov/1WotLGi Further company coverage:

Mar 15 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ Quantitative Report
$115.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.